Dose-response study of SM-13496 in patients with schizophrenia [late Phase 2 study]

Dainippon Sumitomo Pharma Co., Ltd.0 个研究点开始时间: 2005年9月12日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•-Patients who meet the ICD-10 diagnostic criteria for schizophrenia
•-Fresh schizophrenic patients suffering from an initial or recurrent episode or schizophrenic patients receiving antipsychotic drugs, who meet the following inclusion criteria at the time of enrollment
•a) Patients with hallucinations and delusions in the foreground
•b) Patients with delusions in the foreground
•c) Patients with loss of spontaneity and blunted affect in the foreground: Type 1 (fresh, hebephrenic)
•d) Patients with loss of spontaneity and blunted affect in the foreground: Type 2 (chronically illed, fixed symptoms)
•e) Patients presenting with neurosis-like symptoms in the foreground
•f) Patients presenting with depressive symptoms in the foreground
•-Patients aged 18 to less than 65 at the time of informed consent acquisition
•-Patients with a history of malignant syndrome, water intoxication, paralytic ileus or with strong suicidal ideation
•-Patients with Parkinson's disease
•-Patients with HbA1C level of 8.0% or greater, or whose glycoalbumin level is 23.0% or greater
•-Patients who have received electroconvulsive therapy within 6 months (180 days) prior to the first dose of the investigational product

发起方